Mission Therapeutics to Present at Michael J. Fox Foundation’s 15th Annual Parkinson’s Disease Therapeutics Conference

CAMBRIDGE, UK, 10 October 2023 – Mission Therapeutics (“Mission”), a clinical-stage biotech company developing first-in-class therapeutics targeting mitophagy, today announces that its Chief Scientific Officer, Dr Paul Thompson, will give an oral presentation on its experimental drug candidate MTX325 at the 15th Annual Michael J. Fox Foundation’s Parkinson’s Disease Therapeutics Conference on October 19, 2023, in New York.

Dr Thompson will participate in the session titled ‘Advances in Emerging Targets and Therapeutic Development’ where he will discuss Mission’s data demonstrating development of USP30 inhibitors for the treatment of Parkinson’s Disease (PD).

Read more…here.